Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/101310
Campo DC | Valor | Idioma |
---|---|---|
dc.contributor.author | Bernardino, Inês | - |
dc.contributor.author | Dionísio, Ana | - |
dc.contributor.author | Castelo Branco, Miguel | - |
dc.date.accessioned | 2022-08-22T10:01:43Z | - |
dc.date.available | 2022-08-22T10:01:43Z | - |
dc.date.issued | 2022-08-15 | - |
dc.identifier.issn | 2045-2322 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/101310 | - |
dc.description.abstract | Neurofibromatosis type 1 (NF1) is associated with GABAergic dysfunction which has been suggested as the underlying cause of cognitive impairments. Previous intervention trials investigated the statins' effects using cognitive outcome measures. However, available outcome measures have led to inconclusive results and there is a need to identify other options. Here, we aimed at investigating alternative outcome measures in a feasibility trial targeting cortical inhibition mechanisms known to be altered in NF1. We explored the neurochemical and physiological changes elicited by lovastatin, with magnetic resonance spectroscopy and transcranial magnetic stimulation (TMS). Fifteen NF1 adults participated in this randomized, triple-blind, placebo-controlled crossover trial (Clinicaltrials.gov NCT03826940) composed of one baseline and two reassessment visits after lovastatin/placebo intake (60 mg/day, 3-days). Motor cortex GABA+ and Glx concentrations were measured using HERMES and PRESS sequences, respectively. Cortical inhibition was investigated by paired-pulse, input-output curve, and cortical silent period (CSP) TMS protocols. CSP ratios were significantly increased by lovastatin (relative: p = 0.027; absolute: p = 0.034) but not by placebo. CSP durations showed a negative correlation with the LICI 50 ms amplitude ratio. Lovastatin was able to modulate cortical inhibition in NF1, as assessed by TMS CSP ratios. The link between this modulation of cortical inhibition and clinical improvements should be addressed by future large-scale studies. | pt |
dc.language.iso | eng | pt |
dc.relation | info:eu-repo/grantAgreement/FCT/3599-PPCDT/DSAIPA/DS/0041/2020/PT/A clinical documentation system interfacing clinical and data scientist needs to address the COVID challenge | pt |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP/04950/2020 | pt |
dc.relation | info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB/04950/2020 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | pt |
dc.subject.mesh | Adult | pt |
dc.subject.mesh | Humans | pt |
dc.subject.mesh | Lovastatin | pt |
dc.subject.mesh | Neural Inhibition | pt |
dc.subject.mesh | Transcranial Magnetic Stimulation | pt |
dc.subject.mesh | Evoked Potentials, Motor | pt |
dc.subject.mesh | Neurofibromatosis 1 | pt |
dc.title | Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin, as demonstrated by a randomized, triple-blind, placebo-controlled clinical trial | pt |
dc.type | article | - |
degois.publication.firstPage | 13814 | pt |
degois.publication.issue | 1 | pt |
degois.publication.title | Nature | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1038/s41598-022-17873-x | pt |
degois.publication.volume | 12 | pt |
dc.date.embargo | 2022-08-15 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
crisitem.project.grantno | Coimbra Institute for Biomedical Imaging and Translational Research | - |
crisitem.project.grantno | Coimbra Institute for Biomedical Imaging and Translational Research | - |
crisitem.author.researchunit | CIBIT - Coimbra Institute for Biomedical Imaging and Translational Research | - |
crisitem.author.researchunit | CIBIT - Coimbra Institute for Biomedical Imaging and Translational Research | - |
crisitem.author.orcid | 0000-0003-4364-6373 | - |
Aparece nas coleções: | FMUC Medicina - Artigos em Revistas Internacionais I&D CIBIT - Artigos em Revistas Internacionais I&D ICNAS - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Cortical inhibition in neurofibromatosis type 1 is modulated by lovastatin.pdf | 2.21 MB | Adobe PDF | Ver/Abrir |
Citações SCOPUSTM
1
Visto em 17/nov/2022
Visualizações de página
123
Visto em 16/out/2024
Downloads
61
Visto em 16/out/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons